Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.

Athletes can feel the relief a substance gives them long before they can see what it costs. A composite case of cannabis use in a track athlete shows how to assess both.

Rethink “treatment-resistant depression” by adopting difficult-to-treat depression, verifying adequate trials, and stratifying drivers like trauma and inflammation to improve outcomes.

Vortioxetine eases depression in older adults, while cognitive gains stay mixed—showing selective boosts in attention and processing speed, not consistent global improvement.

Ketamine, esketamine, and ECT can rapidly ease suicidal thoughts, but evidence for preventing attempts or deaths remains limited—see what’s proven.

Nearly half of US adults who drink and use cannabis combine them at once; cannabis use disorder drives the trend, signaling urgent screening needs.